This was the stock's second consecutive day of losses.

Franklin Lakes, New Jersey-based Becton, Dickinson and Company (BDX) is a global medical technology company that develops, ...

Matt Miksic from Barclays lowered the price target on Becton, Dickinson, and Company (NYSE:BDX) from $261 to $241, while ...

The stock's rise snapped a four-day losing streak.

Becton Dickinson has 2 warning signs (and 1 which is significant) we think you should know about. NYSE:BDX Revenue & Expenses Breakdown as at May 2025 This technology could replace computers ...

6 analysts have shared their evaluations of Becton Dickinson BDX during the recent three months, expressing a mix of bullish ...

Even though Becton, Dickinson and Company (NYSE:BDX) posted strong earnings, investors appeared to be underwhelmed. We have done some analysis and have found some comforting factors beneath the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.

[Starts Abruptly] I'm Travis Steed, Medical Device Analyst at Bank of America and I'm fortunate to have Tom Polen up next, CEO at Becton, Dickinson. So welcome. Yes. Again, we're not pleased with ...

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) reached a new 52-week low on Wednesday after Morgan Stanley lowered their price target on the stock from $280.00 to $196.00.